10:11 AM EDT, 07/03/2024 (MT Newswires) -- CorMedix ( CRMD ) said Wednesday it has begun outpatient distribution of DefenCath to dialysis centers and vascular access clinics.

DefenCath is a treatment for adult patients with kidney failure receiving chronic hemodialysis to reduce the incidence of catheter-related bloodstream infections, the company said.

The treatment's new drug application was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs on Nov. 15, the biopharmaceutical company added.

CorMedix ( CRMD ) said it started commercialization of DefenCath in the inpatient setting in April.

Price: 4.14, Change: +0.01, Percent Change: +0.36